When 15-month-old Nora received her diagnosis, no one could have predicted the impact it would have on her sister Kayla.

The Revell family hoped a gene therapy could buy time for their sons, who have a rare and fatal disease. After two patients died, the drug’s manufacturer halted dosing under pressure from the FDA.